Medical News

RSS

Advaxis signs definitive purchase agreement with Optimus

Advaxis, Inc., the live, attenuated Listeria monocytogenes immunotherapy company, announced today that it has entered into a definitive purchase agreement with Optimus Capital Partners, LLC d/b/a Optimus Life Sciences Capital Partners, LLC.

20 Jul 2010

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

Net sales for the third quarter of fiscal 2010 were $33,857,000 as compared to $38,240,000 for the same period of the prior fiscal year, a decrease of 11%. Net earnings for the third quarter of fiscal 2010 were $6,424,000 or $0.16 per diluted share, both decreases of 24%, compared to the third quarter of fiscal 2009. (Net earnings include $673,000 in Bioline acquisition costs or $0.01 per diluted share.) Diluted common shares outstanding for fiscal 2010 and 2009 were 41,151,000 and 41,191,000, respectively.

20 Jul 2010

TeleHealth Services announces dates, keynote speakers for TIGRCon10

TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.

20 Jul 2010

Spectranetics announces product reimbursement approval for SLS II

Spectranetics Corporation today announced that the Ministry of Health, Labor and Welfare in Japan has approved product reimbursement to hospitals for the Spectranetics Laser Sheath, which is used for the removal of problematic pacemaker and defibrillator cardiac leads.

20 Jul 2010

Eurotech enters multiple contracts with DynaVox for Catalyst embedded computers

Eurotech, a leading supplier of embedded technologies, products, and systems, today announces multiple contracts with DynaVox to deliver the Catalyst LP and Catalyst Module embedded computers for the DynaVox V, Vmax and Xpress™ alternative augmentative communication (AAC) devices. The combined value of these contracts is nearly 4.2M USD, with deliveries to be made in 2010 and 2011.

20 Jul 2010

MedeAnalytics 10 software platform released

MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its summer 2010 software platform release, MedeAnalytics 10, which offers performance-packed features for proactive alerting and outlier analysis. The release incorporates client input and reflects the company's ongoing investment in its analytic platform. New releases are provided to clients on a semi-annual basis and typically require no upgrades or installations.

20 Jul 2010

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.

20 Jul 2010

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a Certificate of Product Registration from the FDA Philippines, certifying that its Resurgex Select product can now be marketed as a nutritional supplement for cancer patients and other immune-compromised individuals throughout the country.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

EntreMed regains compliance with NASDAQ $1.00 minimum closing bid price requirement

EntreMed, Inc., today announced receipt of a letter from the NASDAQ Stock Market stating that the Company has regained compliance with the $1.00 minimum closing bid price requirement and that, accordingly, it has determined to continue the listing of EntreMed's common stock on the NASDAQ Capital Market.

20 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Frameless radiosurgery can treat most sensitive regions of brain: Study

While four in 10 clinicians use frameless radiosurgery exclusively to treat cranial indications, user data collected at the 5th International Conference of the Novalis Circle, held last month in Munich, Germany, shows that there are still significant opportunities to increase utilization of the effective treatment approach.

20 Jul 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its second quarter 2010 results.

20 Jul 2010

Meridian Bioscience completes acquisition of Bioline group of companies

Meridian Bioscience, Inc., Cincinnati, Ohio announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

20 Jul 2010

Schiff Nutrition's fourth-quarter net sales increase to $49.3 million

Schiff Nutrition International, Inc., today announced results for the fiscal 2010 fourth quarter and year ended May 31, 2010.

20 Jul 2010

First Edition: July 20, 2010

Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.

20 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010